Table II. Regression analysis for treatment effects on tumor growth and Kaplan-Meier analysis for treatment effects on survival. Data are listed as mean with their 95% confidence intervals in parentheses.
| Treatment | n | Growth curveav(d) | r | Tumor doubling time(d)b | Tumor growth delay(d)c | Median survival | 30-days survival | |
|---|---|---|---|---|---|---|---|---|
| LLC | Control | 7 | In(v) = 0.2009d–1.69 | 0.9509 | 3.46 (3.23–3.68) | 8.45 (8.27–8.64) | 18.0 (13.59–26.41) | 0.00 |
| VNP | 7 | In(v) = 0.1583d–1.81 | 0.9733 | 4.44 (4.27–4.61) | 11.43 (11.22–11.64) | 35.0 (25.92–42.08)** | 0.71 | |
| VNPpadhEEnd | 7 | In(v) = 0.1341d–1.95 | 0.9652 | 5.21 (4.99–5.42)† | 14.54 (14.22–14.86)† | 49.0 (33.46–52.54)† | 0.86 | |
| B16F10 | Control | 8 | In(v) = 0.2342d–1.77 | 0.9814 | 2.96 (2.85–3.08) | 7.56 (7.48–7.64) | 11.5 (9.42–13.08) | 0.00 |
| VNP | 8 | In(v) = 0.1186d–1.53 | 0.9586 | 5.84 (5.70–5.98) | 12.90 (12.67–13.05) | 19.5 (13.60–26.65)** | 0.00 | |
| VNPpadhEEnd | 8 | In(v) = 0.0996d–1.70 | 0.9833 | 6.96 (6.86–7.07)† | 17.07 (16.97–17.17)† | 28.5 (16.18–32.82)** | 0.25 |
a Regression growth curves summarize volume (V, cm3) dependence on time (d, days) from initial treatment, with correlation coefficients indicated by r.
b Tumor doubling time was derived from exponential growth curves.
c Growth delay was determined by assessing the time interval to 1000 mm3, (mean ± S.D., ;†p < 0.0001, VNPpadhEEndostatin vs. VNP, **p < 0.01). Median survival time was analyzed by software MedCalc and is listed with their 95% confidence intervals in parentheses. Significance is indicated as **p < 0.01 (in Lewis lung carcinoma (LLC) treatment: VNP vs. control, in B16F10 treatment: VNP vs. control, VNPpadhEEndostatin vs. VNP), ;†p < 0.0001 (in LLC treatment: VNPpadhEEndostatin vs. VNP).